Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718550 | 0.78 | CHRM2 (0.54) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL319049 | 0.73 | CHRM1 (0.70) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL3142425 | 0.70 | CHRM1 (0.81) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL4084782 | 0.70 | CHRM1 (0.76) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL220219 | 0.70 | CHRM1 (0.62) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL7509593 | 0.70 | CHRM1 (0.84) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL3146496 | 0.69 | CHRM2 (0.83) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL13081211 | 0.69 | OPRM1 (0.69) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL44492 | 0.68 | CHRM1 (0.63) | OPRM1OPRK1OPRL1CHRM2CHRM4 | |
| SCHEMBL8863641 | 0.68 | CHRM1 (0.63) | OPRM1OPRK1OPRL1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674789-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-03-09 | — | — | US | claimed |
| US-20090318424-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| US-20090239846-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2009-09-24 | — | — | US | claimed |
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | claimed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | claimed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | claimed |
| EP-2447266-B1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LTD (GB) | 2013-06-12 | — | — | EP | disclosed |
| US-8354416-B2 | 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-5-fluoro-4-methyl-N-(1-methylethyl)benzamide; treating CSBP/p38 kinase mediated diseases; cytokine suppressive anti-inflammatory drugs; mitogen-activated protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2013-01-15 | — | — | US | disclosed |
| EP-1868611-B1 | 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES | GLAXO GROUP LTD (GB) | 2012-11-14 | — | — | EP | disclosed |
| US-8207176-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| EP-2447266-A1 | Pyrimidopyridine compound used as a CSBP/RK/p38 modulator | GLAXO GROUP LIMITED (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20100144755-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2007147103-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| EP-1866311-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | GLAXO GROUP LIMITED (GB) | 2006-11-16 | — | — | US | disclosed |
| US-20060235029-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| US-20060235030-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | US | disclosed |
| WO-2006104889-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258687-A1 | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives | CBR3, CBR1, CYP2S1 | OPRM1 167/4885OPRK1 172/4885OPRL1 273/4885 |
| US-20100144755-A1 | Novel Compounds | MAPKAPK2, CDC42BPB, MAPK8 | OPRM1 3932/4885OPRK1 2001/4885OPRL1 3312/4885 |
| US-20090239846-A1 | Novel Compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | OPRM1 3561/4885OPRK1 1664/4885OPRL1 2999/4885 |
| US-20060235030-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, CDC42BPB | OPRM1 3561/4885OPRK1 1664/4885OPRL1 2999/4885 |
| US-20060235029-A1 | Novel compounds | MAPKAPK2, CDC42BPB, MAPK8 | OPRM1 3932/4885OPRK1 2001/4885OPRL1 3312/4885 |
| US-20090318424-A1 | NOVEL COMPOUNDS | MAPKAPK2, MAPKAPK3, CDC42BPB | OPRM1 3561/4885OPRK1 1664/4885OPRL1 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.